

Special Issue

Robotic Cancer Surgery

Message from the Guest Editor

Cancer kills thousands of people around the world. The current view is that the surgical removal of malignant tumors should also aim to minimize surgical trauma to the patient in order to reduce postoperative morbidity and to improve postoperative quality of life. Therefore, minimally invasive surgery techniques in which special surgical instruments are used, which are inserted through small incisions into the patient's skin. Minimally invasive robotic surgery can further improve surgical outcomes in treating cancer through improved and highly magnified 3DHD visualization, intra-operative near-infrared fluorescence imaging with the visual assessment of tumor tissue and related tissue perfusion. In addition, improving the visualization and high-precision instrument control and movement is a major improvement obtained by robotic instrumentation. However, Clear long-term evidence of the superior curative results of robotic surgery over traditional approaches is controversial. This Special Issue shows the current results of robotic cancer surgery, discusses the limits and shows future possibilities.

Guest Editor

Prof. Dr. Jens Hoepfner

Department of Surgery, University Medical Center of Schleswig-Holstein-Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

Deadline for manuscript submissions

closed (31 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/96963

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)